Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD long-term extension
jRCT2061230004Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of duvakitug in autoimmune colitis and Crohn's disease (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Started Apr 2024; status: active, not recruiting.
02
Drugs
duvakitug
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on jRCT2061230004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230004.